Abstract
Introduction

Despite its clinical relevance, metastasis is the most poorly understood aspect of carcinogenesis. The potential of malignant cells to spread to distant organs is the leading cause of death from breast cancer. Some breast cancer metastases display tissue-specific patterns to distant organs, such as the brain
and bone [3] [4] [5] . Although complex, current studies recognize epithelial-tomesenchymal transitions, cell-to-cell and cell-matrix interactions, activation of specific chemokines/cytokines and proteases, and contributions from signal transduction pathways to the metastastic process [6] .
Contrary to normal breast cancer cells, malignant cells must display enhanced migratory behaviour, the ability to breach blood vessel walls and the dense collagenous matrix surrounding tumours. Additionally, metastatic cells must overcome the dynamics of a foreign microenvironment, to colonize and survive at a distant target site.
Once metastasis has occurred, tumour growth is highly dependent on the ability of tumours to induce their own vascularization [7] . Angiogenesis, which is defined as the formation of new blood vessels from the pre-existing vasculature, is regulated by multiple stimulatory and inhibitory factors that are able to modulate the migration and/or proliferation of microvascular cells [8] . [8] . Vasculature remodelling is regulated by signals derived from receptors for growth factors and chemokines, as well as extracellular matrix (ECM) molecules [9] . There are key events to which malignant cells must adhere to complete angiogenesis: invasion of the surrounding stromal tissue, intravasation and evasion of programmed cell death, arrests with the vasculature at a distant site, extravasation, as well as establishment and growth within a new microenvironment [6] .
Angiogenesis is a normal process in growth and development, as well as in wound healing. However, excessive or insufficient blood vessel formation results in critical diseases
This review will discuss the contributions of integrin-mediated signalling, namely the integrin-linked kinase (ILK) , to the induction and progression of metastasis in breast cancer.
Role of integrins in tumourigenesis
Integrins and their downstream signalling targets, which regulate tissue integrity and function, are essential in breast cancer cell migration (reviewed in Ref. [10] ). The family of 24, heterodimeric adhesion receptors functions as cell-surface glycoproteins, which allows cells to interact with each other and the extracellular environment [11] . Each integrin heterodimer exist as complexes of non-covalently linked ␣ and ␤ subunits, often overlapping with specificity for ECM proteins, such as collagen, fibronectin and laminin (Fig. 4) [11] . Furthermore, the specificity and affinity of an integrin receptor may not be constant with the same receptor on the same cell [11] .
Role of integrins in signalling
Research substantially documents the contributions of ␣6␤1 and ␣6␤4 to breast cancer cell survival, especially in response to cellular stress [38] . Three proteins that have emerged as important regulators of integrin-mediated signalling in breast metastasis are the ILK, and associated adaptor proteins PINCH and parvin [39] [40] [41] [47, 48] . Regulators of ILK activity include a PI3K phosphatase, phosphatase and tensin homolog (PTEN) [48] [49] [50] and the protein phosphatase 2C, ILKAP [51, 52] .
ILK lacks key catalytic domains that are significant to serine/ threonine kinases [50, 51] [52, 53] . The charged FSF motif is similar to the consensus sequence defined for phosphorylation by PDK-2 (phe-X-X-phe-ser-phe(tyr) [52, 53] [62, 63] . In spite of this, the catalytic mechanism of ILK remains unclear [64] .
ILK and binding complexes
The protein-protein interactions ( [66] [67] [68] , are expressed abundantly in the stroma of breast carcinomas, compared to normal breast cells [69] . PINCH1 plays a role in mediating epithelial-mesenchymal transition (EMT), as TGF␤-1 induced PINCH1 mRNA and protein expression, while suppressing epithelial markers (E-cadherin and Zo-1) and increasing fibronectin expression an extracellular assembly [70] . Parvin family members, parvin ␣-, ␤-and ␥-, bind to ILK through one of two calponin homology (CH) domains, and are widely expressed in human mammalian tissues [71] . Binding by parvin ␣ is partially dependent on PIP3, and phosphorylation by cyclin-dependent kinase (CDC2), and MAPK [72] . The biological significance of parvin ␤ is unclear [73] [75] .
ILK in breast cancer
A role for ILK in breast cancer is controversial. Early reports suggested that ILK overexpression resulted in apoptosis in mammary epithelial cells through Akt activation [76] , and reduced the adhesive properties of epithelial cells when plated on integrin ligands [77] . Overexpressed ILK in epithelial cells also disrupted cell-cell contacts, which resulted in anchorage-independent growth and survival [77] . Similarly [81] [82] [83] . [91] . Given the importance of the loss of tumour suppressor function in breast cancers [91] , elucidation of these relationships with ILK would be of great interest.
Regulation of ILK activity in breast cancer: growth factors, cytokines and tumour suppressors
Cancer progression induced by ILK is a result of the induction of its downstream targets. Cross-talk between growth factor pathways and ILK has been identified in its regulation in breast cancer, which appears to be crucial to the eventual progression and invasion of cancer cells. In MCF-7 breast caner cells, ILK overexpression elevated cyclin D1 induction and expression, which involved PI3K and Akt, and resulted in CREB (cAMP response elementbinding) transactivation through binding at the CRE (cAMP
ILK: tumour suppressor?
The [94] , corroborating earlier reports.
Chen et al. described that ILK may not be essential to the progression of breast cancer metastasis, but contributes to the suppression of breast carcinoma cell growth and invasion [101]. In breast cancer cell lines previously identified to contain LOH at 11p15.5, there was a complete loss or significant down-regulation of ILK, whereas the expression was inverse in normal and nonmalignant breast epithelial cells. When an ILK cDNA was re-introduced into MDA-MB-435 breast cancer cells, cells grew at a low saturation density in vivo, compared to untransfected cells.
Additionally, ILK-mediated growth suppression through cell cycle arrest at G1 [101] . From these data, one may suggest ILK a new function as a tumour suppressor, which strongly conflicts with previous reports. What's more, ILK overexpression induced cellular senescence, characterized by larger cell shapes, lower proliferation capacity and loss of ␤-galactosidase activity in rat primary cardiac fibroblasts [102] . This data is an interesting contrast to the well-published role for ILK, and definitely adds to the body of breast carcinoma knowledge especially to sporadic cases where genetic mutations are rare and erratic gene inactivity is prevalent. 
VEGF-and HER2-associated cross-talks with ILK
Conclusions Molecular mechanisms of ILK in other tumours
Consistent with reports in breast cancer, increased ILK expression is noted in other malignant tumours [108] [109] [110] . In gastric carcinomas, increased expression of ILK was detected in over 60% of samples studied; as compared to non-neplastic gastric carcinomas did not overexpress the kinase [108] . Similar results were observed in laryngeal squamous carcinomas [112] . [114, 115] . Dysregulated signalling axes have been shown to increase ILK expression and activity [116] in a variety of cell lines, such as: (i ) endothelin-1 [117] and vitronectin [118] in metastatic ovarian carcinomas; (ii ) TGF␤1 in metastatic melanomas [119] and (iii ) thymosin ␤4 in metastatic colorectal carcinomas [120] . Corroborating [121] . Therefore, based on these collective data, it would be imprudent not to consider ILK as a therapeutic target for breast malignancies and other cancers [83, 122] 
